Please assess the completion status of the following clinical trial:

Trial Title: Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In- and outpatients of either sex~* Able to comply with the protocol~* Having given their written informed consent of their own free will~* Total BPRS (PANSS-derived, 1-7 points) minimum 36 points at baseline~* Schizophrenic or schizophreniform disorder according to DSM-IV criteria (295.10, .30, .40, .90)~* Definite right-handedness (according to the modified Edinburgh Handedness Inventory)~* Age 18 - 50 years~Exclusion Criteria:~* Co-morbid psychiatric axis I disorder (DSM-IV) other than schizophrenia~* Axis II disorder according to DSM-IV~* Present or past history of substance and drug dependence (including alcohol dependence)~* Participation in a clinical trial within the previous three months~* Lack of insight~* Suicidal ideations or aggression against others~* Consumption of caffeine-containing beverages within 6 hours before assessments~* Clinically significant findings in ECG or EEG~* Known intolerance against neuroleptics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): Haloperidol

Based on this trial design, predict the completion outcome and termination type (if applicable).